Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome

doi:10.3748/wjg.v20.i39.14142

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 39

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6993)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

452

WORD

252

HTML

3363

Figures (1-1)

191

Tables (1-3)

176

Sum=4434

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1243

Download

1316

Sum=2559

Oct 21, 2014 (publication date) through Jul 6, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 21, 2014; 20(39): 14142-14155
Published online Oct 21, 2014. doi: 10.3748/wjg.v20.i39.14142

Table 1 Three protocols for prevention of recurrent hepatitis B virus infection after liver transplantation

HBIG-indefinite (HBIG continued for life)	HBIG 10000 IU iv during anhepatic phase;
	then 5000 IU iv daily for 5 d; followed by 800 IU im monthly indefinitely
	Plus
	ETV or TFV indefinitely
HBIG-light (HBIG for first 6 mo only)	HBIG 10000 IU iv during anhepatic phase;
	then 5000 IU iv daily for 5 d; followed by 800 IU im monthly for 6 mo
	Plus
	ETV and/or TFV indefinitely
HBIG-free (No HBIG)	ETV and/or TFV indefinitely

ETV: Entecavir; HBIG: Hepatitis B immune globulin; im: Intramuscular; iv: Intravenous; TFV: Tenofovir. The appropriate annual costs of these are set out in Table 2.

Citation: Ghaziani T, Sendi H, Shahraz S, Zamor P, Bonkovsky HL. Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome. World J Gastroenterol 2014; 20(39): 14142-14155
URL: https://www.wjgnet.com/1007-9327/full/v20/i39/14142.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i39.14142